查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971924

放射性藥物市場分析及預測（至2035年）：依類型、產品、應用、最終使用者、技術、劑型、服務、模式及階段分類

Radiopharmaceuticals Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Form, Services, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 325 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

放射性藥物市場預計將從2024年的184億美元成長到2034年的720億美元，複合年成長率約為14.6%。放射性藥物市場包括用於核子醫學診斷和治療的化合物，這些化合物將放射性同位素與藥物成分結合。這些藥物針對特定器官、組織或細胞受體，從而實現對癌症等疾病的精準成像和治療。推動該市場成長的因素包括醫學影像技術的進步、慢性病盛行率的上升以及放射性標記技術的創新，這些因素共同促進了診斷和治療應用的發展。

放射性藥物市場持續強勁成長，這主要得益於核醫學的進步和對標靶治療日益成長的需求。在診斷領域，PET示蹤劑作為腫瘤學和神經病學應用的關鍵工具，發揮主導作用。 SPECT示蹤劑緊隨其後，反映出其在心臟病學和骨骼影像領域的重要性。在治療領域，放射性標記的單株抗體因其能夠特異性靶向癌細胞而備受關注。胜肽受體放射性核種療法（PRRT）也正在成為治療方法神經內分泌腫瘤的一種有前景的方法。市場正朝著治療診斷學發展，將診斷影像和治療功能結合，從而強化個人化醫療模式。新型放射性同位素的開發和放射化學的進步進一步加速了市場成長。製藥公司與研究機構之間的策略合作正在促進創新並加速臨床試驗。預計對放射性藥物研發投入的增加以及監管支持的加強將繼續保持市場成長動能。

市場區隔
類型 診斷用放射性藥物，治療放射性藥物
產品 Technetium-99m、碘-131、氟脫氧葡萄糖 (FDG)、鎵-68、鎦-177、釔-90、鐳-223、釤-153、鍶-89
目的 腫瘤科、心臟科、神經科、內分泌科、消化科、腎臟科、整形外科
最終用戶 醫院、診斷中心、門診手術中心、學術研究機構、製藥公司及生技公司
科技 迴旋加速器、核子反應爐、線性加速器
形式 液體、固體、氣體
服務 放射性同位素的生產、放射性藥物的生產、品管和測試、法規遵循、物流和配送。
模式 內部、外包
步 臨床前、臨床、商業化

市場概況：

放射性藥物市場呈現市場佔有率分佈動態變化、定價策略競爭激烈以及新產品上市數量激增的特徵。主要企業正致力於創新技術以強化產品系列。市場正經歷著向精準醫療的轉型，推動了對標靶放射性藥物療法的需求。北美地區憑藉其在研發領域的巨額投資，依然保持著市場主導地位。歐洲和亞太地區也正經歷顯著成長，這主要得益於醫療費用支出的成長和技術的進步。對競爭格局的基準研究表明，策略聯盟和併購是市場的重要組成部分。各公司正利用夥伴關係來擴大其全球影響力並強化其產品線。監管影響至關重要，嚴格的監管準則對市場准入和合規性有重大影響。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）是塑造市場動態的關鍵監管機構。隨著市場的不斷發展，對安全性和有效性的關注持續推動創新，並為相關人員提供了盈利的機會。

主要趨勢和促進因素：

放射性藥物市場正經歷強勁成長，這主要得益於核醫和個人化醫療的進步。關鍵趨勢包括放射性藥物在癌症診斷和治療中的應用日益廣泛，精準醫療的重要性也日益凸顯。針對特定癌症類型的新型放射性藥物的研發，有助於提高治療效果和改善患者預後。此外，慢性病的日益增加和人口老化也推動了對診斷影像檢查的需求。混合成像系統等技術創新進一步加速了市場擴張。監管支持和優惠的報銷政策鼓勵對放射性藥物研發進行投資。製藥公司與研究機構之間的策略合作在市場中也佔據重要地位，促進了創新。新興市場醫療基礎設施的不斷完善也帶來了許多機會。專注於拓展產品系列和地理覆蓋範圍的公司將能夠更好地掌握這些趨勢。在持續的科學技術進步和不斷成長的醫療保健需求的推動下，放射性藥物市場預計將保持持續成長。

抑制因素和挑戰：

放射性藥物市場面臨許多重大限制與挑戰。其中一項主要挑戰是嚴格的監管環境。監管機構嚴格的測試和核准流程導致新產品上市延遲，阻礙了中小企業進入市場，並抑制了創新。另一項挑戰是放射性藥物生產高成本。對專用設施和設備的需求增加了營運成本，限制了市場擴張。此外，由於許多放射性藥物的半衰期較短，透過可靠的供應鏈及時交付至關重要，這進一步增加了物流的複雜性。市場也面臨熟練專業人員短缺的問題。核子醫學專業知識對於放射性藥物的安全操作和應用至關重要，但合格人員數量有限。此外，公眾對輻射的認知和擔憂也構成障礙。對安全性的誤解導致人們對放射性藥物療法猶豫不決，從而影響了市場成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 診斷用放射性藥物
    • 用於治療的放射性藥物
  • 市場規模及預測：依產品分類
    • Technetium-99m
    • 碘-131
    • 氟代脫氧葡萄糖（FDG）
    • 鎵-68
    • 鎦-177
    • 釔90
    • 鐳-223
    • 釤153
    • 鍶-89
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 內分泌學
    • 胃腸病學
    • 腎臟病學
    • 整形外科
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷中心
    • 門診手術中心
    • 學術研究機構
    • 製藥公司和生技公司
  • 市場規模及預測：依技術分類
    • 迴旋加速器
    • 核子反應爐
    • 線性加速器
  • 市場規模及預測：依類型
    • 液體
    • 固體的
    • 氣體
  • 市場規模及預測：依服務分類
    • 放射性同位素的生產
    • 放射性藥物的生產
    • 品管和測試
    • 監理合規
    • 物流/配送
  • 市場規模及預測：按模式
    • 內部
    • 外包
  • 市場規模及預測：依階段分類
    • 臨床前
    • 臨床
    • 商業化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • ITM Isotope Technologies Munich
  • Lantheus Medical Imaging
  • Jubilant Radiopharma
  • Curium
  • Telix Pharmaceuticals
  • Bayer Radiopharma
  • NorthStar Medical Radioisotopes
  • Eckert & Ziegler
  • Sofie Biosciences
  • Cardinal Health Radiopharmacy
  • Isotopia Molecular Imaging
  • Radiomedix
  • ImaginAb

第9章 關於我們

簡介目錄
Product Code: GIS34195

Radiopharmaceuticals Market is anticipated to expand from $18.4 billion in 2024 to $72 billion by 2034, growing at a CAGR of approximately 14.6%. The Radiopharmaceuticals Market encompasses compounds used in nuclear medicine for diagnosis and therapy, integrating radioactive isotopes with pharmaceutical agents. These agents target specific organs, tissues, or cellular receptors, enabling precise imaging and treatment of diseases like cancer. The market is driven by advancements in medical imaging, increasing prevalence of chronic diseases, and innovations in radiolabeling techniques, fostering growth in diagnostic and therapeutic applications.

The Radiopharmaceuticals Market is experiencing robust expansion, fueled by advancements in nuclear medicine and increasing demand for targeted therapies. The diagnostic segment leads in performance, particularly with the dominance of PET tracers, which are essential in oncology and neurology applications. SPECT tracers follow, reflecting their continued relevance in cardiology and bone imaging. In the therapeutic segment, radiolabeled monoclonal antibodies are gaining momentum, driven by their specificity in targeting cancer cells. Peptide receptor radionuclide therapy (PRRT) is also emerging as a promising treatment for neuroendocrine tumors. The market is witnessing a shift towards theranostics, combining diagnostic imaging and therapeutic capabilities, enhancing personalized medicine approaches. The development of novel radioisotopes and advancements in radiochemistry are further propelling market growth. Strategic partnerships and collaborations among pharmaceutical companies and research institutions are fostering innovation and accelerating clinical trials. Increasing investments in R&D and regulatory support for radiopharmaceuticals are expected to sustain market momentum.

Market Segmentation
TypeDiagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals
ProductTechnetium-99m, Iodine-131, Fluorodeoxyglucose (FDG), Gallium-68, Lutetium-177, Yttrium-90, Radium-223, Samarium-153, Strontium-89
ApplicationOncology, Cardiology, Neurology, Endocrinology, Gastroenterology, Nephrology, Orthopedics
End UserHospitals, Diagnostic Centers, Ambulatory Surgical Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies
TechnologyCyclotron, Nuclear Reactor, Linear Accelerator
FormLiquid, Solid, Gaseous
ServicesRadioisotope Production, Radiopharmaceutical Manufacturing, Quality Control and Testing, Regulatory Compliance, Logistics and Distribution
ModeIn-house, Outsourced
StagePreclinical, Clinical, Commercial

Market Snapshot:

The radiopharmaceuticals market is characterized by dynamic market share distribution, competitive pricing strategies, and a surge in new product launches. Key players are focusing on innovative technologies to enhance their product portfolios. The market is witnessing a shift towards precision medicine, driving demand for targeted radiopharmaceutical therapies. North America remains a dominant player, with substantial investments in research and development. Europe and Asia-Pacific are also experiencing significant growth, propelled by increasing healthcare expenditure and technological advancements. Competition benchmarking reveals a landscape marked by strategic collaborations and mergers. Companies are leveraging partnerships to expand their global footprint and enhance product offerings. Regulatory influences play a pivotal role, with stringent guidelines impacting market entry and compliance. The U.S. FDA and the European Medicines Agency are key regulatory bodies shaping the market dynamics. As the market evolves, the focus on safety and efficacy continues to drive innovation, offering lucrative opportunities for stakeholders.

Geographical Overview:

The radiopharmaceuticals market is experiencing notable growth across various regions, each presenting unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and substantial investments in nuclear medicine. The region's focus on precision medicine and increasing prevalence of chronic diseases further bolster market expansion. Europe follows, with strong research and development initiatives and regulatory support enhancing market dynamics. The emphasis on innovative cancer therapies and diagnostics contributes to the region's growth. In Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditures and increasing awareness of nuclear medicine's benefits. Emerging economies like China and India are pivotal in this growth trajectory. Latin America and the Middle East & Africa are emerging markets with significant potential. Latin America is witnessing increased adoption of radiopharmaceuticals, driven by improving healthcare infrastructure. Meanwhile, the Middle East & Africa are recognizing the importance of nuclear medicine in advancing healthcare outcomes, presenting lucrative opportunities for market players.

Key Trends and Drivers:

The radiopharmaceuticals market is experiencing robust growth driven by advancements in nuclear medicine and personalized healthcare. Key trends include the increasing use of radiopharmaceuticals in cancer diagnosis and treatment, where precision medicine is gaining prominence. The development of novel radiopharmaceuticals targeting specific cancer types is enhancing treatment efficacy and patient outcomes. Moreover, the rising prevalence of chronic diseases and an aging population are fueling demand for diagnostic imaging. Technological innovations, such as hybrid imaging systems, are further propelling market expansion. Regulatory support and favorable reimbursement policies are encouraging investment in radiopharmaceutical research and development. The market is also witnessing strategic collaborations between pharmaceutical companies and research institutions, fostering innovation. Opportunities abound in emerging markets, where healthcare infrastructure is improving. Companies that focus on expanding their product portfolio and geographic reach are well-positioned to capitalize on these trends. The radiopharmaceuticals market is poised for sustained growth, driven by ongoing scientific advancements and increasing healthcare demands.

Restraints and Challenges:

The radiopharmaceuticals market encounters several formidable restraints and challenges. One significant challenge is the stringent regulatory landscape. Regulatory bodies impose rigorous testing and approval processes, which can delay the introduction of new products. This creates a barrier to entry for smaller companies and stifles innovation. Another challenge is the high cost associated with radiopharmaceutical production. The need for specialized facilities and equipment increases operational expenses, limiting market expansion. Additionally, the short half-life of many radiopharmaceuticals necessitates a robust supply chain to ensure timely delivery, further complicating logistics. The market also faces a shortage of skilled professionals. Expertise in nuclear medicine is essential for the safe handling and application of radiopharmaceuticals, yet there is a limited pool of qualified personnel. Furthermore, public perception and fear of radiation pose hurdles. Misunderstandings about safety can lead to reluctance in adopting radiopharmaceutical treatments, affecting market growth.

Key Players:

Advanced Accelerator Applications, Blue Earth Diagnostics, ITM Isotope Technologies Munich, Lantheus Medical Imaging, Jubilant Radiopharma, Curium, Telix Pharmaceuticals, Bayer Radiopharma, NorthStar Medical Radioisotopes, Eckert & Ziegler, Sofie Biosciences, Cardinal Health Radiopharmacy, Isotopia Molecular Imaging, Radiomedix, ImaginAb

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic Radiopharmaceuticals
    • 4.1.2 Therapeutic Radiopharmaceuticals
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Technetium-99m
    • 4.2.2 Iodine-131
    • 4.2.3 Fluorodeoxyglucose (FDG)
    • 4.2.4 Gallium-68
    • 4.2.5 Lutetium-177
    • 4.2.6 Yttrium-90
    • 4.2.7 Radium-223
    • 4.2.8 Samarium-153
    • 4.2.9 Strontium-89
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Oncology
    • 4.3.2 Cardiology
    • 4.3.3 Neurology
    • 4.3.4 Endocrinology
    • 4.3.5 Gastroenterology
    • 4.3.6 Nephrology
    • 4.3.7 Orthopedics
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Diagnostic Centers
    • 4.4.3 Ambulatory Surgical Centers
    • 4.4.4 Academic and Research Institutes
    • 4.4.5 Pharmaceutical and Biotechnology Companies
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Cyclotron
    • 4.5.2 Nuclear Reactor
    • 4.5.3 Linear Accelerator
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Liquid
    • 4.6.2 Solid
    • 4.6.3 Gaseous
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Radioisotope Production
    • 4.7.2 Radiopharmaceutical Manufacturing
    • 4.7.3 Quality Control and Testing
    • 4.7.4 Regulatory Compliance
    • 4.7.5 Logistics and Distribution
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Clinical
    • 4.9.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Form
      • 5.2.1.7 Services
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Form
      • 5.2.2.7 Services
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Form
      • 5.2.3.7 Services
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Form
      • 5.3.1.7 Services
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Form
      • 5.3.2.7 Services
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Form
      • 5.3.3.7 Services
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Form
      • 5.4.1.7 Services
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Form
      • 5.4.2.7 Services
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Form
      • 5.4.3.7 Services
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Form
      • 5.4.4.7 Services
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Form
      • 5.4.5.7 Services
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Form
      • 5.4.6.7 Services
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Form
      • 5.4.7.7 Services
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Form
      • 5.5.1.7 Services
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Form
      • 5.5.2.7 Services
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Form
      • 5.5.3.7 Services
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Form
      • 5.5.4.7 Services
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Form
      • 5.5.5.7 Services
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Form
      • 5.5.6.7 Services
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Form
      • 5.6.1.7 Services
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Form
      • 5.6.2.7 Services
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Form
      • 5.6.3.7 Services
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Form
      • 5.6.4.7 Services
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Form
      • 5.6.5.7 Services
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Blue Earth Diagnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ITM Isotope Technologies Munich
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Lantheus Medical Imaging
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Jubilant Radiopharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Curium
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Telix Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Bayer Radiopharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 NorthStar Medical Radioisotopes
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eckert & Ziegler
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sofie Biosciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cardinal Health Radiopharmacy
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Isotopia Molecular Imaging
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Radiomedix
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 ImaginAb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us